Swipe to navigate through the articles of this issue
This study investigates whether the threat of litigation induces firms to provide safer products in a regulated industry. I analyze whether removing litigation risk or “delitigation” of product liability is associated with a change in the safety of vaccines. Using U.S. nationwide and state-level data, I find that vaccines that were licensed after legislation that preempted most product liability lawsuits are associated with a significantly higher incidence of adverse events than were vaccines that were licensed under a previous regime that permitted consumers to sue. Oaxaca decomposition suggests that the difference is due to the policy change. The results suggest that product safety deteriorates when consumers are no longer able to sue manufacturers.
Please log in to get access to this content
To get access to this content you need the following product:
Bedford, H., & Lansley, M. (2007). More vaccines for children? Parents’ views. Vaccine, 25(45), 7818–7823. CrossRef
Biddle, T. M., Green, E. M., Mannix, R. J. & Winkelman, S. L. (2002). Industry standards as a source of liability for trade associations and association members. Retrieved August 10, 2014 from http://www.crowell.com/documents/DOCASSOCFKTYPE_ARTICLES_506.pdf.
Boulianne, N., De Serres, G., Duval, B., Joly, J. R., Meyer, F., Dery, P., et al. (1991). Major measles epidemic in the region of Quebec despite a 99% vaccine coverage. Canadian Journal of Public Health, 82(3), 189–190.
Brisson, M., Gay, N. J., Edmunds, W. J., & Andrews, N. J. (2002). Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine, 20(19–20), 2500–2507. CrossRef
Brown, S. J., & Warner, J. B. (1985). Using daily stock returns: The case of events studies. Journal of Financial Economics, 14, 3–31. CrossRef
Bruesewitz v. Wyeth. (2011). 562 U.S. 223. Retrieved March 27, 2017 from https://supreme.justia.com/cases/federal/us/562/09-152/.
Centers for Disease Control and Prevention. (1997). Poliomyelitis prevention in the United States. MMWR Recommendations and Reports, 46 (RR-3) (pp. 1–25).
Centers for Disease Control and Prevention. (1999a). Rotavirus vaccine (rotashield) and intussusception. Retrieved January 3, 2013 from http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm.
Centers for Disease Control and Prevention. (1999b). Withdrawal of rotavirus vaccine recommendation. MMWR. Morbidity and Mortality Weekly Report, 48(43), 1007.
Christie, C. D., Marx, M. L., Marchant, C. D., & Reising, S. F. (1994). The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. New England Journal of Medicine, 331(1), 16–21. CrossRef
Classen, J. B. (2014). Review of vaccine induced immune overload and the resulting epidemics of type 1 diabetes and metabolic syndrome. Journal of Molecular and Genetic Medicine, S1, 25–29.
Colafrancesco, S., Perricone, C., Tomljenovic, L., & Shoenfeld, Y. (2013). Human papilloma virus vaccine and primary ovarian failure: Another facet of the autoimmune/inflammatory syndrome induced by adjuvants. American Journal of Reproductive Immunology, 70(4), 309–316. CrossRef
Coulter, H. L., & Fisher, B. L. (1991). A shot in the dark. New York: Penguin Group.
Dell’Antonia, K. J. (2013). Will parents still turn down an ‘anti- cancer vaccine’? Retrieved March 3, 2017 from https://mobile.nytimes.com/blogs/parenting/2013/06/19/will-parents-still-turn-down-an-anti-cancer-vaccine/.
Dodd, D. (2003). Benefits of combination vaccines: Effective vaccination on a simplified schedule. American Journal of Managed Care, 9, S6–S12.
Gatti, A. M., & Montanari, S. (2017). New quality-control investigations on vaccines: Micro- and nanocontamination. International Journal of Vaccines and Vaccination. doi: 10.15406/ijvv.12017.15404.00072.
Gottsdanker v. Cutter Laboratories. (1960). 182 cal.App.2d 602, 6 cal.Rptr. 320, 79 a.L.R.2d 290 (cal.App. 1 dist. Jul 12). Retrieved March 1, 2017 from http://law.justia.com/cases/california/court-of-appeal/2d/182/602.html.
Harper, D. M., & Williams, K. B. (2010). Prophylactic HPV vaccines: Current knowledge of impact on gynecologic premalignancies. Discovery Medicine, 10(50), 7–17.
Hinrichsen, V. L., Kruskal, B., O’Brien, M. A., Lieu, T. A., & Platt, R. (2007). Using electronic medical records to enhance detection and reporting of vaccine adverse events. Journal of the American Medical Informatics Association, 14(6), 731–735. CrossRef
Institute of Medicine. (1993). The children’s vaccine initiative: Achieving the vision. Washington, DC: National Academy Press. Retrieved January 15, 2014 from http://www.nap.edu/catalog/2224.html.
Institute of Medicine. (2000). Vaccines for the 21st century: A tool for decisionmaking. Retrieved January 15, 2014 from http://www.nap.edu/catalog/5501.html.
Institute of Medicine. (2013). The childhood immunization schedule and safety. Washington, DC: The National Academies Press.
Joskow, P. L. (2005). Regulation and deregulation after 25 years: Lessons learned for research in industrial organization. Review of Industrial Organization, 26, 169–193. CrossRef
Kesselheim, A. (2011). Safety, supply, and suits—Litigation and the vaccine industry. New England Journal of Medicine, 364(16), 1485–1487. CrossRef
Kessler, D. A. (1993). Introducing medwatch. A new approach to reporting medication and device adverse effects and product problems. JAMA, 269(21), 2765–2768. CrossRef
Kessler, D., & Vladeck, D. (2008). A critical examination of the FDA’s efforts to preempt failure-to-warn claims. Georgetown Law Journal, 96, 461–495.
King, A. J., Van Der Lee, S., Mohangoo, A., Van Gent, M., Van Der Ark, A., & Van De Waterbeemd, B. (2013). Genome-wide gene expression analysis of bordetella pertussis isolates associated with a resurgence in pertussis: Elucidation of factors involved in the increased fitness of epidemic strains. PLoS ONE, 8(6), e66150. CrossRef
Lasker, C. A. (2011). Private securities litigation reform act: Safe harbor for the innocent or modern day Port of Tortuga for the buccaneers of Wall Street? Journal of Corporation Law, 36(3), 654–675.
Legal Information Institute. (2013). Rule 37. Failure to make disclosures or to cooperate in discovery; sanctions. Retrieved August 3, 2014 from http://www.law.cornell.edu/rules/frcp/rule_37.
Little, D. T., & Ward, H. R. (2012). Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Report. doi: 10.1136/bcr-2012-006879.
Little, D. T., & Ward, H. R. (2014). Adolescent premature ovarian insufficiency following human papillomavirus vaccination: A case series seen in general practice. Journal of Investigative Medicine High Impact Case Reports. doi: 10.1177/2324709614556129.
Manning, R. L. (1994). Changing rules in tort law and the market for childhood vaccines. Journal of Law and Economics, 37(1), 247–275. CrossRef
Marin, M., Broder, K. R., Temte, J. L., Snider, D. E., & Seward, J. F. (2010). Use of combination measles, mumps, rubella, and varicella vaccine. MMWR Recommendations and Reports, 59(RR-3), 1–12.
National Vaccine Information Center (NVIC). (2013). Dose- adjusted graphs and tables. Retrieved September 2, 2013 from http://www.medalerts.org/vaersdb/doses/index.php.
Oaxaca, R. (1973). Male-female wage differentials in urban labor markets. Internationl Economic Review, 14, 693–709. CrossRef
Otake, T. (2016). Cervical cancer vaccine suit filed over side effects. Retrieved March 3, 2017 from http://www.japantimes.co.jp/news/2016/07/27/national/crime-legal/cervical-cancer-vaccine-suit-filed-over-side-effects/#.WLlxW28rJph.
Philipson, T. J., & Sun, E. (2008). Is the Food and Drug Administration safe and effective? Journal of Economic Perspectives, 22(1), 85–102. CrossRef
Philipson, T. J., Sun, E., & Goldman, D. (2011). The effects of product liability exemption in the presence of the FDA. In D. P. Kessler (Ed.), Regulation vs litigation: Perspectives from economics and law (pp. 137–163). Chicago: University of Chicago Press.
Polinsky, M., & Shavell, S. (2010). The uneasy case for product liability. Harvard Law Review, 123(6), 1438–1492.
Quinn, M., Babb, P., Jones, J., & Allen, E. (1999). Effect of screening on incidence of and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics. BMJ, 318(7188), 904–908. CrossRef
Romanowski, B. (2011). Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Human Vaccine, 7(2), 161–169. CrossRef
Salk, J. (1984). Statement on national childhood vaccine injury compensation act. Retrieved May 11, 2014 from http://files.eric.ed.gov/fulltext/ED255480.pdf.
Shavell, S. (1980). Strict liability versus negligence. Journal of Legal Studies, 9(1), 1–25. CrossRef
Shavell, S. (1984a). A model of the optimal use of liability and safety regulation. Rand Journal of Economics, 15(2), 271–280. CrossRef
Shavell, S. (1984b). Liability for harm versus regulation of safety. Journal of Legal Studies, 13(2), 357–374. CrossRef
Sotomayor, S. (2011). Dissent of Bruesewitz v. Wyeth LLC. Retrieved March 27, 2017 from https://supreme.justia.com/cases/federal/us/562/09-152/dissent.html.
Struck, M. (1996). Vaccine R&D success rates and development times. Nature Biotechnology, 14, 591–593. CrossRef
Tartof, S. Y., Lewis, M., Kenyon, C., White, K., Osborn, A., Liko, J., et al. (2013). Waning immunity to pertussis following 5 doses of DTaP. Pediatrics, 131(4), e1047–e1052. CrossRef
Toner v. Lederle Laboratories. (1987). 828 f.2d 510. Retrieved March 27, 2017 from https://law.resource.org/pub/us/case/reporter/F2/828/828.F2d.510.84-3906.html.
Trebilcock, M., & Veel, P.-E. (2013). Chapter 22: No-fault accident compensation systems. In J. Arlen (Ed.), Research handbook on the economics of torts (pp. 588–607). Northampton, MA: Edward Elgar.
U.S. Congress House of Representatives: Committee on Energy and Commerce. (1984). Hearings before the subcommittee on health and environment on H.R. 5810, 98th Congress, 2nd session. Retrieved March 1, 2014 from http://babel.hathitrust.org/cgi/pt?id=mdp.39015042797467;view=1up;seq=1.
Wakefield, A. J., Murch, S. H., Anthony, A., Linnell, J., Casson, D. M., Malik, M., et al. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet, 351(9103), 637–641. (retracted 2010). CrossRef
Whitaker, J. A., Ovsyannikova, I. G., & Poland, G. A. (2015). Adversomics: A new paradigm for vaccine safety and design. Expert Review of Vaccines, 14(7), 935–947. CrossRef
White, H. (1980). A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica, 48, 817–838. CrossRef
- Is “Delitigation” Associated with a Change in Product Safety? The Case of Vaccines
- Publication date
- Springer US
Neuer Inhalt/© Stellmach, Neuer Inhalt/© Maturus, Pluta Logo/© Pluta